Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 윤지영 | * |
dc.date.accessioned | 2017-10-27T11:45:30Z | - |
dc.date.available | 2017-10-27T11:45:30Z | - |
dc.date.issued | 2017 | * |
dc.identifier.issn | 0363-9762 | * |
dc.identifier.other | OAK-20948 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/237219 | - |
dc.description.abstract | Purpose In patients with Parkinson disease (PD), decreased serum ceruloplasmin levels have been observed. This study investigated a correlation between serum ceruloplasmin - along with its related serum markers -and striatal presynaptic dopaminergic denervation measured with 123 I-FP-CIT SPECT. Methods We analyzed a total of 141 de novo patients divided into 2 groups: the PD group (107 patients with PD) and the disease control group (34 patients with vascular pseudoparkinsonism, essential tremor, or drug-induced parkinsonism). Serum ceruloplasmin and related serum markers, such as copper, iron, total iron-binding capacity, and ferritin, were measured. Specific binding ratios of the striatum, caudate nucleus, putamen, and posterior putamen were obtained by 123 I-FP-CIT SPECT. Results There was no difference in the serum markers, except for ceruloplasmin, between the 2 groups. Ceruloplasmin level was significantly lower in PD patients with longer symptom duration (>2 years) than in the disease control group (21.4 ± 3.4 vs 24.0 ± 3.8, P = 0.03). Serum ceruloplasmin had a significant correlation with specific binding ratios of the striatum, caudate nucleus, and putamen in a subgroup with longer symptom duration (P = 0.01, P = 0.02, P = 0.02, respectively, for the subgroup with symptom duration >1 year, and P < 0.01, P < 0.01, P = 0.04, respectively, for the subgroup with symptom duration >2 years). Conclusions Decrease in serum ceruloplasmin had a positive correlation with a decrease in dopamine transporter density in PD patients with symptom duration of more than 1 year. © 2017 Wolters Kluwer Health, Inc. All rights reserved. | * |
dc.language | English | * |
dc.publisher | Lippincott Williams and Wilkins | * |
dc.subject | 123 I-FP-CIT SPECT | * |
dc.subject | ceruloplasmin | * |
dc.subject | dopamine | * |
dc.subject | Parkinson disease | * |
dc.title | Serum ceruloplasmin and striatal dopamine transporter density in Parkinson disease: Comparison with 123I-FP-CIT spect | * |
dc.type | Article | * |
dc.relation.issue | 9 | * |
dc.relation.volume | 42 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 675 | * |
dc.relation.lastpage | 679 | * |
dc.relation.journaltitle | Clinical Nuclear Medicine | * |
dc.identifier.doi | 10.1097/RLU.0000000000001734 | * |
dc.identifier.wosid | WOS:000407889900004 | * |
dc.identifier.scopusid | 2-s2.0-85021116700 | * |
dc.author.google | Song Y.S. | * |
dc.author.google | Kim J.-M. | * |
dc.author.google | Kim K.J. | * |
dc.author.google | Yun J.Y. | * |
dc.author.google | Kim S.E. | * |
dc.contributor.scopusid | 윤지영(55216408300) | * |
dc.date.modifydate | 20231221115919 | * |